Corona puts a spanner in the works for large IO Biotech lung trial
The coronavirus outbreak will have consequences for IO Biotech. The development of the company's potential lung cancer drug, which is currently being tested in combination with MSD's blockbuster Keytruda, has been delayed. "We are doing everything we can to minimize the delay," says the CEO.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.